All In Biotech

Drug Trial Radar · NCT06918002

Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients

A Phase 3, Open-label, Controlled, Randomized Study of Newly Diagnosed Multiple Myeloma Treatment, Designed to Evaluate the Efficacy and Safety of the Elranatamab-lenalidomide Combination as a Replacement for Chemotherapy Followed by Autologous Stem Cell Transplant in the Consolidation Phase, and to Compare Elranatamab With Standard of Care in the Maintenance Phase

Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 824 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

824

Planned (sponsor's estimate)

Start

Jul 9, 2025

Primary completion

May 2036

Study completion May 2036

Sponsor

Lead sponsor
Intergroupe Francophone du MyelomeResearch network
Sponsor type
Research network
Collaborators
Pfizer
First posted
Apr 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 69 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed as a multicenter, randomized, parallel groups, open-label, phase 3 study in subjects with untreated newly diagnoses Multiple Myeloma eligible for ASCT. 824 patients will be enrolled in this study from approximately 70 study sites. The 2 parts in the Treatment Phase are described below. Part 1: Induction/ASCT/Consolidation Phase (1:1 Randomization) After the screening period, patients will be randomly allocated (1:1) to either: * Arm A (standard of care arm): standard induction therapy with 4 cycles of D-VRd, followed by HDCT (Melphalan) + ASCT, D-VRd consolidation therapy * Arm B (experimental arm): standard induction therapy with 4 cycles of D-VRd, followed by elranatamab and lenalidomide consolidation therapy. Part 2: Maintenance Phase (1:1 Re-randomization) Patients will be re-randomized (1:1) and will enter the Maintenance Phase upon completion of consolidation therapy. • Arm C (standard of care arm): daratumumab + lenalidomide approx 2 years. Subjects with a negative MRD (for at least 12 months) after 24 cycles of daratumumab-lenalidomide will discontinue daratumumab and continue with lenalidomide monotherapy until disease progression, or study cut-off date (whichever occurs first). Subjects who did not achieve MRD negativity for at least 12 months after 24 cycles of daratumumab-lenalidomide will continue to receive daratumumab-lenalidomide until: * MRD negativity for at least 12 months is reached. Subjects will then continue with lenalidomide monotherapy until disease progression, or study cut-off date (whichever occurs first). * Disease progression * Or study cut-off date (whichever occurs first). * Arm D (experimental arm): elranatamab. Approx 2 years. Subjects with a negative MRD (for at least 12 months) after receiving M22 administration of elranatamab will discontinue study treatment with elranatamab. Subjects who did not achieve MRD negativity for at least 12 months after M22 elranatamab administration will continue to receive elranatamab, every 24 weeks, until MRD negativity for at least 12 months is reached, disease progression, or study cut-off date (whichever occurs first).

Conditions

  • Multiple Myeloma, Newly Diagnosed

Interventions

  • ElranatamabDrug

    Elranatamab is given to arm B patients in association with lenalidomide (for consolidation) and arm D patients in monotherapy (for maintenance) as experimental arms

  • Lenalidomide (Revlimid®)Drug

    In association with daratumumab, bortezomib and dexamethasone (Arm A), in association with elranatamab (Arm B), and in combination with daratumumab in maintenance (Arm C)

  • Daratumumab SC (Darzalex)Drug

    Daratumumab is given in association with bortezomib, lenalidomide and dexamethasone in induction therapy (all patients) and consolidation arm A

  • Autologous Stem Cell TransplantationProcedure

    ASCT is performed in consolidation for Arm A patients after induction therapy with D-VRD

  • Bortezomib (Velcade®)Drug

    Bortezomib is given in associtaion with daratumumab, lenalidomide and dexamethasone in induction (all patients) and consolidation Arm A

  • DexamethasoneDrug

    Dexamethasone is given in association with daratumumab, bortezomib and lenalidomide in induction (all patients) and consolidation Arm A

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 (induction/consolidation) from Randomization 1 (R1): to assess whether consolidation therapy with elranatamab and lenalidomide is superior to standard of care, in terms of Minimal Residual Disease (MRD) negativity rateTime frame: at end of consolidation, up to 36 months
  2. Part 2 (maintenance) from Randomization 2 (R2): to assess whether maintenance therapy with elranatamab is superior to standard of care, in terms of Progression Free Survival (PFS).Time frame: from the date of second randomization to the date of confirmed PD (IMWG criteria,) or death from any cause, whichever came first, assessed up to 93 monts
  3. Key secondary objectives: Part 1 (induction/consolidation) from R1: to assess whether consolidation therapy with elranatamab and lenalidomide is superior, in terms of PFSTime frame: PFS defined as the time interval from the date of first randomization to the date of confirmed Progression Disease (IMWG criteria) or death from any cause, whichever occurs first., assessed up to 128 months
  4. Key secondary objectives: Part I (induction/consolidation) from R1: to assess whether consolidation therapy with elranatamab and lenalidomide is superior to standard of care, in terms of Overal Survival (OS)Time frame: up to 128 months

Locations

69 sites in 2 countries. Site status is shown where the registry gives one.

  • Institut Jules Bordet

    Brussels, Belgium · Not yet recruiting

  • Cliniques Universitaires Saint Luc

    Brussels, Belgium · Not yet recruiting

  • Grand Hopital Charleroi

    Charleroi, Belgium · Not yet recruiting

  • CHU de Liège

    Liège, Belgium · Not yet recruiting

  • CHU UCL Namur

    Yvoir, Belgium · Not yet recruiting

  • CHU Amiens

    Amiens, France · Recruiting

  • CHU Angers

    Angers, France · Recruiting

  • Ch Annecy Genevois

    Annecy, France · Recruiting

  • Centre Hospitalier d'Argenteuil Victor Dupouy

    Argenteuil, France · Recruiting

  • Centre Hospitalier H. Duffaut

    Avignon, France · Recruiting

  • Centre hospitalier de la Côte Basque

    Bayonne, France · Recruiting

  • CHU Besançon

    Besançon, France · Recruiting

  • Centre Hospitalier Simone Veil

    Blois, France · Recruiting

  • Hôpital Avicenne

    Bobigny, France · Recruiting

  • CHU Bordeaux - Hopital Haut Lévêque - Centre F. Magendi

    Bordeaux, France · Recruiting

  • CH Fleyriat

    Bourg-en-Bresse, France · Recruiting

  • CHRU Brest - Hôpital A. Morvan

    Brest, France · Recruiting

  • CHU Caen - Côte de Nacre

    Caen, France · Recruiting

  • Centre Hospitalier William Morey

    Chalon-sur-Saône, France · Recruiting

  • CHMS Centre Hospitalier Métropole Savoie

    Chambéry, France · Recruiting

  • Hopital Louis Pasteur

    Chartres, France · Recruiting

  • Hôpital d'Instruction des Armées Percy

    Clamart, France · Recruiting

  • Chu Estaing

    Clermont-Ferrand, France · Recruiting

  • Centre Hospitalier Sud Francilien

    Corbeil-Essonnes, France · Recruiting

  • CHU Henri Mondor

    Créteil, France · Recruiting

  • CHU Dijon

    Dijon, France · Recruiting

  • Institut de cancérologie de Bourgogne

    Dijon, France · Recruiting

  • Centre Hospitalier de Dunkerque

    Dunkirk, France · Recruiting

  • CHU de Grenoble

    Grenoble, France · Recruiting

  • CHU de la Réunion Site SUD (Terre Sainte)

    La Réunion, France · Recruiting

  • CHD Vendée

    La Roche-sur-Yon, France · Recruiting

  • Hopital Monod

    Le Havre, France · Recruiting

  • CH Le mans

    Le Mans, France · Recruiting

  • CHRU Hôpital Claude Huriez

    Lille, France · Recruiting

  • Centre Hospitalier Universitaire (CHU) de Limoges

    Limoges, France · Recruiting

  • Centre Léon Bérard

    Lyon, France · Recruiting

  • Centre Hospitalier Lyon Sud

    Lyon, France · Recruiting

  • Grand Hopital Est Francilien (GHEF) Site de Meaux

    Meaux, France · Recruiting

  • Hôpital de Mercy (CHR Metz-Thionville)

    Metz, France · Recruiting

  • Centre de Recherche Clinique / GHT des Landes

    Mont-de-Marsan, France · Recruiting

Showing 40 of 69 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.